EA201500579A1 - Комбинированная терапия с использованием воласертиба - Google Patents
Комбинированная терапия с использованием воласертибаInfo
- Publication number
- EA201500579A1 EA201500579A1 EA201500579A EA201500579A EA201500579A1 EA 201500579 A1 EA201500579 A1 EA 201500579A1 EA 201500579 A EA201500579 A EA 201500579A EA 201500579 A EA201500579 A EA 201500579A EA 201500579 A1 EA201500579 A1 EA 201500579A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- volasertiba
- combined therapy
- volasertib
- cytarabine
- csf
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 abstract 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 abstract 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 abstract 2
- 229960000684 cytarabine Drugs 0.000 abstract 2
- SXNJFOWDRLKDSF-STROYTFGSA-N volasertib Chemical compound C1CN([C@H]2CC[C@@H](CC2)NC(=O)C2=CC=C(C(=C2)OC)NC=2N=C3N(C(C)C)[C@@H](C(N(C)C3=CN=2)=O)CC)CCN1CC1CC1 SXNJFOWDRLKDSF-STROYTFGSA-N 0.000 abstract 2
- 229950003081 volasertib Drugs 0.000 abstract 2
- VNTHYLVDGVBPOU-QQYBVWGSSA-N (7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 VNTHYLVDGVBPOU-QQYBVWGSSA-N 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 229960003334 daunorubicin citrate Drugs 0.000 abstract 1
- 229960000390 fludarabine Drugs 0.000 abstract 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12195162 | 2012-11-30 | ||
| PCT/EP2013/074862 WO2014083058A1 (en) | 2012-11-30 | 2013-11-27 | Combination therapy with volasertib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201500579A1 true EA201500579A1 (ru) | 2015-12-30 |
Family
ID=47325907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201500579A EA201500579A1 (ru) | 2012-11-30 | 2013-11-27 | Комбинированная терапия с использованием воласертиба |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20140154304A1 (enExample) |
| EP (1) | EP2925343A1 (enExample) |
| JP (1) | JP2016501208A (enExample) |
| KR (1) | KR20150090091A (enExample) |
| CN (1) | CN104812400A (enExample) |
| AU (1) | AU2013351180A1 (enExample) |
| BR (1) | BR112015011748A2 (enExample) |
| CA (1) | CA2889787A1 (enExample) |
| CL (1) | CL2015001258A1 (enExample) |
| EA (1) | EA201500579A1 (enExample) |
| IL (1) | IL238174A0 (enExample) |
| IN (1) | IN2015DN03075A (enExample) |
| MX (1) | MX2015006592A (enExample) |
| PH (1) | PH12015501113A1 (enExample) |
| WO (1) | WO2014083058A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9867831B2 (en) * | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| CN104306336B (zh) * | 2014-11-18 | 2016-08-24 | 河北天成药业股份有限公司 | 枸橼酸柔红霉素脂质体注射液的制备工艺 |
| CA3219061A1 (en) * | 2015-11-11 | 2017-05-18 | Celator Pharmaceuticals, Inc. | Assays and methods for selecting a treatment regimen for a subject with leukemia |
| WO2021242859A1 (en) * | 2020-05-27 | 2021-12-02 | Duke University | Compositions and methods for sensitizing acute myeloid leukemias to chemotherapy |
| CN116785296B (zh) * | 2023-06-06 | 2025-09-05 | 河北渤腾医药技术有限公司 | 一种plk1的抑制剂及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004076454A1 (de) | 2003-02-26 | 2004-09-10 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| WO2008074572A1 (en) * | 2006-12-20 | 2008-06-26 | Universitätsklinikum Hamburg-Eppendorf | Use of tri-substituted glycerol compounds for the treatment of hematological malignancies |
| SI3300601T1 (sl) * | 2007-02-16 | 2022-05-31 | Rotalec Ip Holdings Llc | Fiksna razmerja med zdravili za zdravljenje vrst hematopoetskega raka in proliferativnih motenj |
| US9358233B2 (en) * | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
-
2013
- 2013-11-25 US US14/088,948 patent/US20140154304A1/en not_active Abandoned
- 2013-11-27 EP EP13795533.2A patent/EP2925343A1/en not_active Withdrawn
- 2013-11-27 BR BR112015011748A patent/BR112015011748A2/pt not_active IP Right Cessation
- 2013-11-27 MX MX2015006592A patent/MX2015006592A/es unknown
- 2013-11-27 KR KR1020157014213A patent/KR20150090091A/ko not_active Withdrawn
- 2013-11-27 AU AU2013351180A patent/AU2013351180A1/en not_active Abandoned
- 2013-11-27 WO PCT/EP2013/074862 patent/WO2014083058A1/en not_active Ceased
- 2013-11-27 EA EA201500579A patent/EA201500579A1/ru unknown
- 2013-11-27 CA CA2889787A patent/CA2889787A1/en not_active Abandoned
- 2013-11-27 CN CN201380062203.7A patent/CN104812400A/zh active Pending
- 2013-11-27 JP JP2015544453A patent/JP2016501208A/ja active Pending
-
2015
- 2015-04-12 IL IL238174A patent/IL238174A0/en unknown
- 2015-04-13 IN IN3075DEN2015 patent/IN2015DN03075A/en unknown
- 2015-05-11 CL CL2015001258A patent/CL2015001258A1/es unknown
- 2015-05-20 PH PH12015501113A patent/PH12015501113A1/en unknown
-
2017
- 2017-03-03 US US15/448,660 patent/US20170173023A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150090091A (ko) | 2015-08-05 |
| MX2015006592A (es) | 2015-08-05 |
| IN2015DN03075A (enExample) | 2015-10-02 |
| CN104812400A (zh) | 2015-07-29 |
| JP2016501208A (ja) | 2016-01-18 |
| US20170173023A1 (en) | 2017-06-22 |
| WO2014083058A1 (en) | 2014-06-05 |
| PH12015501113A1 (en) | 2015-08-17 |
| US20140154304A1 (en) | 2014-06-05 |
| AU2013351180A1 (en) | 2015-04-30 |
| CL2015001258A1 (es) | 2015-10-02 |
| EP2925343A1 (en) | 2015-10-07 |
| IL238174A0 (en) | 2015-05-31 |
| BR112015011748A2 (pt) | 2017-07-11 |
| CA2889787A1 (en) | 2014-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| EP3686200A3 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
| WO2015009726A3 (en) | Medical uses of cd38 agonists | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| EA201591924A1 (ru) | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 | |
| PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| WO2016090024A3 (en) | Combination therapy for treatment of cancer | |
| EA201500579A1 (ru) | Комбинированная терапия с использованием воласертиба | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| PH12017502046A1 (en) | Salts and prodrugs of 1-methyl-d-tryptophan | |
| MX382776B (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
| EA201792294A1 (ru) | Комбинированное лечение (варианты) с применением серибантумаба | |
| WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| NZ720273A (en) | Preparations and methods for treating a gd2 positive cancer | |
| WO2015035410A8 (en) | Cancer therapy | |
| HK1219896A1 (zh) | 使用4-氨基-2-(2，6-二氧代-呱啶-3-基)-异吲哚啉-1，3-二酮治疗和控制中枢神经系统癌症的方法和组合物 | |
| WO2015038896A3 (en) | Wilforlide a for overcoming chemotherapy resistance | |
| MX2015014905A (es) | Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos. | |
| MX2014001221A (es) | Metodo para tratar el cancer mediante el uso combinado de farmacos. |